Search results
Showing 2801 to 2850 of 3765 results for treatment
NICE has developed a medtech innovation briefing (MIB) on SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea .
Complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique) (IPG56)
Evidence-based recommendations on complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique). This involves complete surgical tumour removal with intraoperative heated chemotherapy, and is followed by postoperative intraperitoneal chemotherapy.
View recommendations for IPG56Show all sections
Sections for IPG56
Guidance on the use of vinorelbine for the treatment of advanced breast cancer (TA54)
This guidance has been updated and replaced by NICE guideline CG81.
Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis (TA35)
This guidance has been updated and replaced by NICE technology appraisal guidance 373.
This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes
serology is likely to remain positive for some time following successful treatment of infection in most patients. However, little is...
NICE has developed a medtech innovation briefing (MIB) on TopClosure Tension Relief System for wound closure .
Comparator, Outcome) P: people hospitalised because of COVID-19 I: treatment with different doses of casirivimab and imdevimab C: •...
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)
This guidance has been updated and replaced by NICE technology appraisal guidance 766.
Inhaled insulin for the treatment of type 1 and type 2 diabetes (TA113)
In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete. Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications. 25 January 2008
This guidance has been updated and replaced by NICE technology appraisal guidance 385.
In development Reference number: GID-TA11365 Expected publication date: TBC
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]
In development Reference number: GID-TA11386 Expected publication date: TBC
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)
This guidance has been updated and replaced by NICE technology appraisal guidance 1071.
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
In development Reference number: GID-TA10935 Expected publication date: TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
In development Reference number: GID-TA11569 Expected publication date: TBC
Evidence-based recommendations on percutaneous vertebroplasty for spinal metastases. This involves injecting a special bone cement into the spine to relieve pain and stabilise the fracture site.
Endovascular stent–graft placement in thoracic aortic aneurysms and dissections (IPG127)
Evidence-based recommendations on endovascular stent–graft placement in thoracic aortic aneurysms and dissections. This involves placing a stent covered in graft material inside the aorta under X-ray guidance.
View recommendations for IPG127Show all sections
Sections for IPG127
Transilluminated powered phlebectomy for varicose veins (IPG37)
Evidence-based recommendations on transilluminated powered phlebectomy for varicose veins. This involves using a special light passed underneath the skin to see the veins and removing them by suction.
View recommendations for IPG37Show all sections
Sections for IPG37
Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment (HTG759)
Late stage assessment (LSA) guidance on bed frames for adults in acute medical or surgical hospital wards.
Medicines management for people receiving social care in the community (QS171)
This quality standard covers assessing if people need help with their medicines and deciding what medicines support is needed to enable people to manage their medicines. It also includes communication between health and social care staff, to ensure people have the medicines support they need. It describes high-quality care in priority areas for improvement.
View quality statements for QS171Show all sections
deliver the injection. Patient adherence to treatment may be improved with anoral rather than injectable treatment.A large...
In development Reference number: GID-TA11663 Expected publication date: TBC
experiencing wound dehiscence following surgery, which may reduce the costs of treatment. However, the committee acknowledged that there...
core set of relevant health outcome measures should be used for trials of treatments for ME/CFS and managing symptoms of ME/CFS? Any...
no evidence base for clinicians to make decisions with regards to the treatment options available. Antimuscarinics are used first-line...
Thoracoscopic excision of mediastinal parathyroid tumours (IPG247)
Evidence-based recommendations on thoracoscopic excision of mediastinal parathyroid tumours. This involves operating on the tumour using a flexible camera inserted through small cuts in the chest (keyhole surgery).
View recommendations for IPG247Show all sections
Sections for IPG247
This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.
Exploratory work regarding the use of bevacizumab in the treatment of eye conditions [ID422]
Discontinued Reference number: GID-TA11205
Digital platforms to support cardiac rehabilitation: early value assessment (HTG764)
Early value assessment (EVA) on digital platforms to support cardiac rehabilitation.
Safe staffing for nursing in adult inpatient wards in acute hospitals (SG1)
This guideline covers organisational and managerial approaches to safe nurse staffing of inpatient wards for people aged 18 and over in acute hospitals. It aims to ensure that patients receive the nursing care they need, regardless of the ward to which they are allocated, the time of the day, or the day of the week.
there is no evidence exploring the psychological impact of the different treatments for ectopic pregnancy. However, the emotional impact...
the current clinical evidence,including the impact of gammaCore on all treatments and care as well as itslong-term benefits, would be...
Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)
This guideline has been updated and replaced by NICE guideline NG101.
Discontinued Reference number: GID-MT130
potentially improve survival if people recover enough to have more effective cancer treatments. The outcomes of interest are:-...
description of patient selection, and details of adjunctive medical and surgical treatments. Outcomes should include GORD symptoms,...
directly compare eltrombopag with non-thrombopoietin receptor agonist treatments routinely used in UK clinical practice. Any explanatory...
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.
This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance and NICE accredited sources
Cellvizio confocal endomicroscopy system for characterising pancreatic cysts (MIB69)
Advice on the use of Cellvizio confocal endomicroscopy system (CLS) for characterising pancreatic cysts to aid local decision-making
procedure, whether or not other adjunctive treatments are used. Research should document adjunctive treatments and details...
This guideline covers managing cataracts in adults aged 18 and over. It aims to improve care before, during and after cataract surgery by optimising service organisation, referral and surgical management, and reducing complications. It further aims to improve the availability of information for people with cataracts before, during and after cataract surgery.
Clarification on demonstrating patient access to medicines and treatments recommended by NICE Technology Appraisal (TA) or Highly Specialised Technologies (HST) guidance.
The clinical and cost effectiveness of proton pump inhibitors for the treatment of dyspepsia (TA7)
This guidance has been replaced by NICE guideline CG17. [Replaced by NICE guideline CG184]
icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)
NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .
Single-incision short sling mesh insertion for stress urinary incontinence in women (IPG566)
Evidence-based recommendations on single-incision short sling mesh insertion for stress urinary incontinence in women. This involves putting 2 short slings around the tube that carries urine from the bladder to support it.
PICO negative pressure wound dressings for closed surgical incisions (HTG509)
Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions.
Evidence-based recommendations on radiofrequency-assisted liver resection. This involves using high-frequency radio waves to remove the cancerous part of the liver with minimal blood loss.
View recommendations for IPG211Show all sections
Sections for IPG211